Ligand id: 7990

Name: atezolizumab

No information available.
Summary of Clinical Use
In May 2016, the US FDA granted accelerated approval for atezolizumab as a therapy for locally advanced or metastatic urothelial carcinoma, in patients whose disease has progressed during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
As a result of the Phase III clinical trial, NCT02008227 (assessing MPDL3280A vs. docetaxel as a treatment for locally advanced or metastatic non-small cell lung cancer unresponsive to platinum therapy), FDA approval was granted in October 2016 for NSCLC that has progressed during or following platinum-containing chemotherapy, for tumours with EGFR or ALK gene abnormalities. Patients in NCT02008227 receiving atezolizumab lived 4.2 months longer than those treated with docetaxel chemotherapy.
Mechanism Of Action and Pharmacodynamic Effects
MPDL3280A binds to PD-L1 and inhibits its binding to its receptor, PD-1 (programmed death 1) which acts as a negative regulator of the immune system, limiting the expansion and survival of CD8+ T cells. As PD-L1 is overexpressed on many human cancer cell types the PD-L1/PD-1 mechanism effects immune evasion by tumour cells. MPDL3280A inhibits activation of PD-1, thereby reversing the PD-1 effect on T-cell inactivation and enhances the T-cell-mediated immune response to neoplasms. The Fc region of MPDL3280A is modified so that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).